PHASE 2 TRIAL: EVALUATION OF SILYMARIN FOR TREATMENT OF PATIENTS WITH COVID-19

EVALUATION OF THE INHIBITORY ACTIVITIES OF SILYMARIN AGAINST SARS-CoV-2 . COVID-19

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

PACTR

Registry ID

PACTR202012898601759

Enrollment

314

Registered

2020-12-04

Start date

2020-12-20

Completion date

Unknown

Last updated

2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

COVID 19

Interventions

Silymarin based combination

Chloroquine

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Positive SARS COV-2 RT-PCR 2. Age > 6 weeks and above 2. Had not received any of the study drugs for at least one day

Exclusion criteria

Exclusion criteria: 1. Unable to take oral medications 2. Pregnancy 4. Severe immunocompromised 5. Known contraindications to study drugs

Design outcomes

Primary

Measure	Time frame
Clinical recovery from start of treatment	—

Secondary

Measure	Time frame
Viral clearance (SARS COV 2 RT-PCR) ;Safety and tolerability:	—

Countries

Nigeria

Contacts

Public ContactSimeon;Emmanuel Omale;Nnadi

Safety lead;Microbiologist

soluv04@gmail.com;eennadi@gmail.com+2348037009165;+2348068124819

Outcome results

None listed

Source: PACTR (via WHO ICTRP) · Data processed: Aug 9, 2026